Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease - Wikidata - wikimedia - TriplyDB

Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease

Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease

http://www.wikidata.org/entity/Q28482356

about

Glial Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy Protective Effects of Streblus asper Leaf Extract on H2O2-Induced ROS in SK-N-SH Cells and MPTP-Induced Parkinson's Disease-Like Symptoms in C57BL/6 Mouse The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice.PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma status Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.Localization of peroxisome proliferator-activated receptor alpha (PPARα) and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) in cells expressing the Ca(2+)-binding proteins calbindin, calretinin, and parvalbumin in the adult rat hippocamp Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.Mast cells, glia and neuroinflammation: partners in crime?Endocannabinoids, related compounds and their metabolic routes.Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice.Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs.Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.Delay of morphine tolerance by palmitoylethanolamide.Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia.Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections.Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects.Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease.Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons.Palmitoylethanolamide Ameliorates Hippocampal Damage and Behavioral Dysfunction After Perinatal Asphyxia in the Immature Rat Brain.Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence.N-Palmitoylethanolamine Supplementation for Long-Lasting, Low-Dosed Morphine Antinociception.A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review.

P2860

Q26747533-BB22E5AB-FBBB-4606-9DCD-3402838E0901 Q26776171-B8A6EB6F-F848-4BA8-9F1E-17740443B552 Q30393313-CFB935EE-DA23-4447-99B0-E99C80B1A57F Q31122398-4B92B244-0AAE-4240-80F4-3E251A938027 Q33725859-DD799D01-78AD-41EE-9BA1-97E3D7920920 Q34203838-B6509F4D-161F-4151-B969-57D7447D7CE5 Q35078274-AB58B677-16CA-457E-B10C-13C3BD1273F6 Q35132611-8C4EB0DF-7499-481E-92D5-DE4E70EB999E Q35381177-E8B610DD-23BB-4C51-92F2-ECBBD140EAF6 Q36775237-261F3021-FABE-422F-A1E6-9FBDC723ADDE Q37256315-2091284E-9BB3-499B-B8DB-931D9B557019 Q38118187-ECFB44D6-13EE-464C-B9EE-5FE4E0BF6F5D Q38137173-859C0184-F6F0-42E6-9551-5C371E147D82 Q38262964-D3E51EF0-D9F8-402F-AA82-9CE63E27A746 Q38645776-D7B1830F-881A-439E-B20C-AD0C4B09C20C Q38777732-556A2A4C-F437-4CC1-9379-828143BAE828 Q39230043-18E9E59A-E97E-4F1D-9E81-7C3EBF7FB288 Q40855302-EE7EDADF-EEA6-4104-802B-D624C9D44D22 Q41467663-BBDB12EA-0D45-485E-81B1-2796A8316E01 Q41908176-316D2EAB-A4BD-426A-9FC9-538BFAC2EE5F Q41912809-EE9B6725-FF9C-4577-981A-D805082499CC Q42220056-166BE448-5911-49D7-805F-04267015A8F4 Q42719351-B61E778A-FA94-4696-BEE5-A19612DC76D9 Q48139053-F2C5F302-95C3-4B20-9486-34DA80296FBE Q48238673-C7459C06-BA23-40C7-839C-0B38D137646E Q50526982-351D2202-981E-4D7C-8077-0CD801A37710 Q52584461-D50BB771-13BA-40DB-8833-1860346D8D30 Q52632555-06FCF13F-5BC1-433F-94B7-930ADA9E23E8 Q55094909-59D04EB7-9071-4DF6-9563-D58E9611DB18 Q55236616-8538FED0-C8AD-40FB-86F7-4B07C8FB3143

P2860

Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease

http://www.wikidata.org/entity/Q28482356

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Neuroprotective activities of ...... l model of Parkinson's disease

@ast

Neuroprotective activities of ...... l model of Parkinson's disease

@en

Neuroprotective activities of ...... l model of Parkinson's disease

@nl

type

label

Neuroprotective activities of ...... l model of Parkinson's disease

@ast

Neuroprotective activities of ...... l model of Parkinson's disease

@en

Neuroprotective activities of ...... l model of Parkinson's disease

@nl

prefLabel

Neuroprotective activities of ...... l model of Parkinson's disease

@ast

Neuroprotective activities of ...... l model of Parkinson's disease

@en

Neuroprotective activities of ...... l model of Parkinson's disease

@nl

P1433

Q28482356-732F1A4E-EE38-4564-875E-9DAC23B27B0F

P1476

Q28482356-A7BE6D51-C196-4812-90CB-9790671B5EEB

P2093

Q28482356-215EB899-D911-4BCF-AC7B-7D338338F74F

Q28482356-AB472C7D-D6FE-48B6-8B97-04A77C43FEEF

Q28482356-E5B5E10E-3475-4A60-A8BB-7AAFE9000580

P2860

Q28482356-02DB4B27-E1A0-4CA2-929D-E1160FB0ED07

Q28482356-07F02085-CE07-4E53-AE0D-F324403D7535

Q28482356-12A6EB5C-C5CE-4BED-9C8C-EE7CE0BD899B

Q28482356-157E33C7-DF6F-42BF-B844-D69178E62269

Q28482356-16B4D22F-008F-4847-9871-CC51730C011C

Q28482356-1B5833D4-26DC-4E63-8705-0536F6B73CAE

Q28482356-290221B1-87D2-4C47-8309-CAF3747C7CF3

Q28482356-2E697D25-AE2C-4E03-BD5E-747DF906A1A2

Q28482356-3484DA0C-9288-4D79-ADB6-58BE0EDA1B31

Q28482356-3F0C34FC-E191-4C26-B605-F68A020BFA18

P304

Q28482356-EFD3E7FC-7D9B-452C-A2E1-551184BBA82A

P31

Q28482356-CCA958F4-6208-4614-B16F-D874002D2114

P3181

Q28482356-6DADB927-2447-4C33-9BD7-E1824CDE8B81

P356

Q28482356-D52A9976-7C70-4328-825E-CA18435C3367

P407

Q28482356-E8E4FDD0-4009-44FB-9B30-BDDC6A3F7DC7

P433

Q28482356-6076DE55-687F-4D31-85BE-2F238C3FDAE7

P478

Q28482356-80F3613D-DA7D-42EF-A31A-805D353E52AB

P50

Q28482356-3411CA7B-9C0F-42EB-8016-0F34C162360D

Q28482356-66EE7E07-55B8-443A-A966-C5380EE8BEB7

P577

Q28482356-5505B38A-7C84-4D4C-9DEE-5A684BD9E5E5

P5875

Q28482356-6C21016E-0D17-4C84-A21F-79791C29CA8D

P698

Q28482356-5D58CEAC-EDFA-4B48-B17F-2D1AF8B8DD71

P921

Q28482356-76D04960-B461-4C23-B1E5-53BA91E6530A

P932

Q28482356-2CC313A6-2931-4CEA-963D-984D32F908FF

P3181

P356

JOURNAL.PONE.0041880

P1433

P1476

Neuroprotective activities of ...... l model of Parkinson's disease

@en

P2093

Daniela Impellizzeri

http://www.w3.org/2001/XMLSchema#string

Emanuela Esposito

http://www.w3.org/2001/XMLSchema#string

Irene Paterniti

http://www.w3.org/2001/XMLSchema#string

P2860

Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide

Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α

Parkinson's disease: mechanisms and models

Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury.

The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.

Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.

Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.

The palmitoylethanolamide family: a new class of anti-inflammatory agents?

Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.

Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α.

P304

e41880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2074223

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0041880

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Emanuela Mazzon

Salvatore Cuzzocrea

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230716302

http://www.w3.org/2001/XMLSchema#string

P698

22912680

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3422290

http://www.w3.org/2001/XMLSchema#string